Skip to main content
Premium Trial:

Request an Annual Quote

Santaris to Present Phase IIa Data on HCV Drug

Premium

This story has been updated to correct the date of Santaris' presentation.

Santaris Pharma announced this week that it will present final phase IIa data on its microRNA-targeting hepatitis C therapy miravirsen at the European Association for the Study of the Liver annual meeting this month.

“The data show that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent antiviral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA that was sustained well beyond four weeks beyond the end of therapy,” the company said.

Santaris reported earlier this year that it is aiming for a second phase II trial to study the miR-122-targeting drug in combination with a direct-acting antiviral agent (GSN 1/12/2012).

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.